BetterLife Pharma has announced its first set of positive data showing the anti-depressant effects of an LSD derivative – 2-bromo-LSD (TD-0148A).
Clearmind Medicine has signed an R&D agreement with Bar-Ilan University to explore the efficacy of its compound for the treatment of addiction.
New findings from a citizen science study suggest that microdosing psychedelics could be a valuable tool in the battle against poor mental health.
Diamond Therapeutics has now dosed the first cohort of its Phase I low-dose psilocybin clinical trial.
A study undertaken over a five-year period has shown that a single dose of ketamine improved thinking and reasoning in people who had expressed thoughts of...
The largest psilocybin therapy clinical trial ever conducted, investigating psilocybin for treatment-resistant depression (TRD), has achieved its primary endpoint.
Kicking off the Microdose Wonderland conference in Miami, Cybin Inc announced it will be moving its psilocybin analogue – CYB003 – into clinical trials.
The findings from a Phase II A/B study, which is the world’s first study on ketamine-assisted psychotherapy for alcohol use disorder, will be published in the...
Biotech company, Mind Medicine Inc, is expanding its drug development pipeline with the launch of a programme to develop R(-)-MDMA for the treatment of social anxiety...